"We thank LifeScience Alley for this recognition - a direct reflection of the hard work and many contributions of our talented employees in Minnesota," said David L. Martin, CSI president and chief executive officer. "This honor recognizes CSIs innovative technology to safely treat routine and complex peripheral arterial disease (PAD) cases. The Stealth 360° removes harmful plaque from arteries in a very short treatment time in the hospital or physicians office. Our technologies, combined with our growing wealth of clinical data, are helping physicians achieve a new standard of care for PAD patients to save limbs and lives."
The Stealth 360° utilizes CSIs proven orbital mechanism of action, which protects healthy tissue while removing difficult-to-treat plaque in patients with peripheral arterial disease. The Stealth 360° eliminates the large capital equipment portion of its predecessor product for a more compact and easier-to-use system. With simple, convenient speed adjustments on the handle, physicians can vary the speed of orbit and have greater control to achieve shorter procedure times and a high percentage of plaque reduction. The device also reduces set-up and staff time.
About LifeScience Alley
LifeScience Alley is an international leader in sharing best practices, and is the largest state-based life sciences trade association in the United States. With a 26-year track record of providing valuable services and results-oriented outcomes to its members, LifeScience Alley enables business success through educating workforces, influencing state and federal public policy, supporting advancement in research and technological innovation, and fostering industry connections. The Associations membership employs approximately 250,000 Minnesotans and its reach extends throughout the Midwest and Canada. For additional information, visit: www.LifeScienceAlley.org.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Stealth 360°TM, Diamondback 360® and Predator 360® PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007, the Predator 360° in March 2009 and for the Stealth 360° in March 2011. To date, more than 55,000 PAD procedures have been performed using CSI's PAD systems in leading institutions across the United States.
CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.
For more information, visit the companys website at www.csi360.com.
Posted by Sean Fenske, Editor-in-Chief, MDT